Introduction & Objective: SmartStart CGM is a structured educational program for current users of continuous glucose monitoring (CGM) designed for use on a mobile phone. It presents basic and advanced information about using CGM and interpreting CGM data. We assessed the effects of SmartStart CGM on CGM knowledge level and time in range vs. baseline.

Methods: This proof of concept study enrolled 20 adults with type 1 diabetes on intensive insulin therapy (n=15 on hybrid closed-loop insulin pump therapy, n=5 on multiple daily injections). After enrollment, participants answered 20 "welcome check" questions to assess baseline knowledge. Upon completion of 7 interactive content modules, they answered the same 20 questions as a “final check.” Participants’ time in range 70-180 mg/dL (%TIR) and time below range <70 mg/dL (%TBR) were obtained at baseline and 6 weeks post-completion. Changes from baseline in CGM knowledge and time in range were measured.

Results: Average duration of CGM use prior to enrollment was 31.5+/-19.3 months. The mean CGM knowledge score rose from 38% to 88%. At 6 weeks post-completion, 72.7% of participants with %TIR of <70% at baseline (n=11) showed a clinically meaningful increase of at least 5%. Among participants with baseline %TIR of at least 70% (n=9), 77.8% maintained/increased %TIR up to 4%; 22.2% showed an increase of at least 5%. The proportion of participants reaching %TBR of <4% rose from 70% to 100%. The percentage of participants reaching both %TIR of at least 70% and %TBR of <4% increased from 25% to 65%.

Conclusion: The results of this proof of concept study strongly suggest that completion of SmartStart CGM was associated with increased CGM knowledge, increased %TIR and reduced %TBR.

Disclosure

M.P. Holloway: Other Relationship; Dexcom, Inc. Consultant; Insulet Corporation. T. Grace: Speaker's Bureau; Sanofi, Novo Nordisk, Eli Lilly and Company, Dexcom, Inc. Employee; Dexcom, Inc. C. Parkin: Consultant; Abbott, embecta, Dexcom, Inc., Insulet Corporation, Tandem Diabetes Care, Inc., Roche Diabetes Care, PharmaSens, MannKind Corporation, Provention Bio, Inc.

Funding

Diabetes Center Berne; Dexcom Inc (MED00032)

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.